The Proliferative Vitreoretinopathy (PVR) drugs in development market research report provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Proliferative Vitreoretinopathy (PVR). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Proliferative Vitreoretinopathy (PVR) by eight companies/universities/institutes. The top development phase for Proliferative Vitreoretinopathy (PVR) is preclinical with four drugs in that stage. The Proliferative Vitreoretinopathy (PVR) pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Proliferative Vitreoretinopathy (PVR) pipeline products market are: Kaplan Medical Center, Novartis and Aldeyra Therapeutics.

The key targets in the Proliferative Vitreoretinopathy (PVR) pipeline products market include Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25), Platelet Derived Growth Factor (PDGF) , and Transforming Growth Factor Beta 1 (TGFB1).

The key mechanisms of action in the Proliferative Vitreoretinopathy (PVR) pipeline product include Dihydrofolate Reductase (DHFR or EC 1.5.1.3) Inhibitor with one drug in Phase III. The Proliferative Vitreoretinopathy (PVR) pipeline products include four routes of administration with the top ROA being Oral and four key molecule types in the Proliferative Vitreoretinopathy (PVR) pipeline products market including Small Molecule, and Aptamer.

Proliferative Vitreoretinopathy (PVR) overview

Proliferative vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation, or complications from diabetes.

For a complete picture of Proliferative Vitreoretinopathy (PVR)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.